Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERACLES: MaaT013 for Steroid-Refractory GI-aGVHD
NCT03359980Phase 2Completed
- Sponsor
- MaaT Pharma
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Live Biotherapeutic Products, Device-based Delivery
- Countries
- 3
01
Overview
A Phase 2 trial of MaaT013 in graft-versus-host disease (GVHD), sponsored by MaaT Pharma. Started Aug 2018; status: completed.
02
Drugs
MaaT013
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03359980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359980.